Atara Q3 2021 Earnings Report
Key Takeaways
Atara Biotherapeutics reported financial results for the third quarter of 2021, highlighting positive data from the Phase 3 ALLELE study for Tab-cel and progress with ATA188 for multiple sclerosis. The company is preparing for regulatory submissions and continues to advance its CAR T programs.
Positive data from the pivotal Phase 3 ALLELE study reinforces the transformative potential of Tab-cel.
Significant regulatory progress for Tab-cel with an imminent EU MAA submission and clarity on FDA requirements for BLA submission planned for Q2 2022.
ATA188 data demonstrates durable, clinically meaningful disability improvement and possible remyelination in patients with progressive multiple sclerosis.
Atara is making good progress and expects to submit an IND for ATA3219, an off-the-shelf, allogeneic CD19 CAR T immunotherapy targeting B-cell malignancies, in Q1 2022.
Atara
Atara
Atara Revenue by Segment
Forward Guidance
Atara believes that its cash as of September 30, 2021, together with the $45.0 million upfront payment received as a result of our entry into the Pierre Fabre Commercialization Agreement, is sufficient to fund planned operations into the second quarter of 2023